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A B S T R A C T
Background
Diabetic macular oedema (DMO) is a thickening of the central retina, or the macula, and is associated with long-term visual loss
in people with diabetic retinopathy (DR). Clinically significant macular oedema (CSMO) is the most severe form of DMO. Almost
30 years ago, the Early Treatment Diabetic Retinopathy Study (ETDRS) found that CSMO, diagnosed by means of stereoscopic
fundus photography, leads to moderate visual loss in one of four people within three years. It also showed that grid or focal laser
photocoagulation to the macula halves this risk. Recently, intravitreal injection of antiangiogenic drugs has also been used to try to
improve vision in people with macular oedema due to DR.
Optical coherence tomography (OCT) is based on optical reflectivity and is able to image retinal thickness and structure producing
cross-sectional and three-dimensional images of the central retina. It is widely used because it provides objective and quantitative
assessment of macular oedema, unlike the subjectivity of fundus biomicroscopic assessment which is routinely used by ophthalmologists
instead of photography. Optical coherence tomography is also used for quantitative follow-up of the effects of treatment of CSMO.
Objectives
To determine the diagnostic accuracy of OCT for detecting DMO and CSMO, defined according to ETDRS in 1985, in patients
referred to ophthalmologists after DR is detected. In the update of this review we also aimed to assess whetherOCTmight be considered
the new reference standard for detecting DMO.
Search methods
We searched the Cochrane Database of Systematic Reviews (CDSR), the Database of Abstracts of Reviews of Effects (DARE), the
Health Technology Assessment Database (HTA) and the NHS Economic Evaluation Database (NHSEED) (The Cochrane Library
2013, Issue 5), Ovid MEDLINE, Ovid MEDLINE In-Process and Other Non-Indexed Citations, Ovid MEDLINE Daily, Ovid
OLDMEDLINE (January 1946 to June 2013), EMBASE (January 1950 to June 2013), Web of Science Conference Proceedings
Citation Index - Science (CPCI-S) (January 1990 to June 2013), BIOSIS Previews (January 1969 to June 2013), MEDION and the
Aggressive Research Intelligence Facility database (ARIF). We did not use any date or language restrictions in the electronic searches for
trials. We last searched the electronic databases on 25 June 2013. We checked bibliographies of relevant studies for additional references.
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Selection criteria
We selected studies that assessed the diagnostic accuracy of anyOCTmodel for detectingDMOorCSMO in patients withDRwhowere
referred to eye clinics. Diabetic macular oedema and CSMO were diagnosed by means of fundus biomicroscopy by ophthalmologists
or stereophotography by ophthalmologists or other trained personnel.
Data collection and analysis
Three authors independently extracted data on study characteristics and measures of accuracy. We assessed data using random-effects
hierarchical sROC meta-analysis models.
Main results
We included 10 studies (830 participants, 1387 eyes), published between 1998 and 2012. Prevalence of CSMO was 19% to 65%
(median 50%) in nine studies with CSMO as the target condition. Study quality was often unclear or at high risk of bias for QUADAS
2 items, specifically regarding study population selection and the exclusion of participants with poor quality images. Applicablity was
unclear in all studies since professionals referring patients and results of prior testing were not reported. There was a specific ’unit of
analysis’ issue because both eyes of the majority of participants were included in the analyses as if they were independent.
In nine studies providing data on CSMO (759 participants, 1303 eyes), pooled sensitivity was 0.78 (95% confidence interval (CI) 0.72
to 0.83) and specificity was 0.86 (95% CI 0.76 to 0.93). The median central retinal thickness cut-off we selected for data extraction
was 250 µm (range 230 µm to 300 µm). Central CSMO was the target condition in all but two studies and thus our results cannot be
applied to non-central CSMO.
Data from three studies reporting accuracy for detection of DMO (180 participants, 343 eyes) were not pooled. Sensitivities and
specificities were about 0.80 in two studies and were both 1.00 in the third study.
Since this review was conceived, the role of OCT has changed and has become a key ingredient of decision-making at all levels of
ophthalmic care in this field. Moreover, disagreements between OCT and fundus examination are informative, especially false positives
which are referred to as subclinical DMO and are at higher risk of developing clinical CSMO.
Authors’ conclusions
Using retinal thickness thresholds lower than 300 µm and ophthalmologist’s fundus assessment as reference standard, central retinal
thickness measured with OCT was not sufficiently accurate to diagnose the central type of CSMO in patients with DR referred to
retina clinics. However, at least OCT false positives are generally cases of subclinical DMO that cannot be detected clinically but still
suffer from increased risk of disease progression. Therefore, the increasing availability of OCT devices, together with their precision
and the ability to inform on retinal layer structure, now make OCT widely recognised as the new reference standard for assessment of
DMO, even in some screening settings. Thus, this review will not be updated further.
P L A I N L A N G U A G E S U M M A R Y
Optical coherence tomography measurement of central retinal thickness to diagnose diabetic macular oedema
Background
Diabetic macular oedema (DMO) is a thickening of the central part of the retina, the macula, that may affect people with diabetic
retinopathy (DR). Diabetic retinopathy is a complication of diabetes in which the retina (a layer of tissue at the back of the eye)
becomes progressively damaged. Diabetic macular oedema is detected by means of visual examination by an ophthalmologist. The most
severe form of DMO - clinically significant macular oedema (CSMO) - is associated with sight loss in the long-term. This condition
is treatable. Laser photocoagulation (where a laser is used to burn off blood vessels) has been used for many years to reduce the risk
of visual loss. More recently, antiangiogenic therapy (which prevents fluid leakage from retinal vessels) has been approved to try to
improve vision.
Review question
Optical coherence tomography (OCT) is based on how light is reflected. It can be used to measure retinal thickness. We originally
aimed to assess the accuracy of OCT for diagnosing diabetic macular oedema (DMO), as well as to investigate differences in diagnostic
2Optical coherence tomography (OCT) for detection of macular oedema in patients with diabetic retinopathy (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
performance. However, the role of OCT is expanding so in the update of this review we also aimed to assess whether OCT might be
considered the new standard for diagnosing DMO.
Search date
This review is updated as of June 2013.
Study characteristics
Our review included 10 studies (830 participants, 1387 eyes) published between 1998 and 2012. Nine of these studies investigated
the ability of OCT to diagnose CSMO.
Study funding sources
There were no overt declarations of potential conflicts of interest in terms of the manufacturer of the OCT device being involved in
funding the research.
Key results
We found that OCT retinal thickness measurement is not sufficiently accurate to detect CSMO, involving the centre of the macula,
using clinical fundus examination as the reference standard. Of 10 patients with diabetic retinopathy, 5 of whom have CSMO, 1 of 5
with no CSMO would be wrongly diagnosed as having CSMO, and about 1 of 5 with CSMO would be missed.
However, researchers have found that disagreements between OCT and clinical examination occur because OCT can detect early,
subclinical retinal thickening in people without CSMO and more advanced retinopathy. They suggested that such cases of subclinical
macular oedema are followed more closely, since they are at increased risk of progression to CSMO. Furthermore, OCT is an essential
tool to manage antiangiogenic therapy in patients with DMO and is believed by many to be a new reference standard for its diagnosis.
Quality of the evidence
Study quality was often unclear because of incomplete reporting or because it was at risk of bias. Specifically, this concerned how
patients were selected in the study, who referred them and how, and exclusion of those for whom poor quality images were obtained.
Furthermore, many studies included both patient’s eyes, which is a problem in data analyses.
B A C K G R O U N D
Target condition being diagnosed
Diabetes mellitus results in considerable morbidity and mortality,
affecting about 180 million people worldwide (WHO 2002). The
total number of people with diabetes is expected to rise to an esti-
mated 300 million cases by the year 2025, with the most signifi-
cant increases in developing countries. The increase is thought to
be the result of population growth, ageing, obesity and sedentary
lifestyle (King 1998).
Approximately 25% of people with diabetes have at least some
form of diabetic retinopathy (DR) and the incidence increases
with the duration of the diabetes. At 10 years the prevalence of
retinopathy in diabetic patients is 7%, after 25 years it is more
than 90% (Aiello 1998). In developed countries, NIH 1995 found
that diabetic eye disease represents the leading cause of blindness
in adults under 75 years of age.
There are twomain complications ofDR causing visual loss (Aiello
2003; Kiire 2013). These are proliferative retinopathy and dia-
betic macular oedema (DMO). Proliferative DR is the occurrence
of retinal neovascularisation caused by retinal ischaemia and may
lead to severe visual loss due to intraocular haemorrhage and reti-
nal detachment. Diabetic macular oedema is a thickening of the
central portion of the retina, called the macula. It is often associ-
ated with deposits of lipoproteins or hard exudates and may lead
to gradual loss of central vision due to deterioration of the retinal
cells. Clinically significant macular oedema (CSMO) is the most
severe form of DMO.Diabetic macular oedema increases with the
duration of diabetes and its prevalence is 5% within the first five
years after diagnosis and 15% at 15 years (Aiello 1998). A review
of studies found a prevalence of CSMO in people with diabetes
ranging from 2% to almost 10% (Williams 2004).
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According to the Diabetic Retinopathy Study (DRS) Group, the
risk of severe visual loss at two years was 3.2% for eyes with non-
proliferative DR (DRS 1987). The presence of CSMO increases
the risk of moderate visual loss to approximately 30% to 50%
depending on the level of baseline visual acuity. It is an indication
for grid or focal laser treatment (Javitt 1989).
Stereoscopic fundus photography was used to diagnose macu-
lar oedema in the Early Treatment Diabetic Retinopathy Study
(ETDRS 1985) and has been used as a standard method in re-
search. In clinical practice, ophthalmologists routinely use con-
tact or non-contact stereoscopic fundus biomicroscopy to diag-
nose macular oedema. In primary care, other healthcare profes-
sionals may use direct ophthalmoscopy or non-stereoscopic fun-
dus photography to detect DR, but these methods do not allow
the examiner to perceive retinal thickening as a primary sign of
macular oedema. Only hard exudates or indirect signs, such as
haemorrhages ormicroaneurysms in themacula, can be identified.
Telemedicine is increasingly used for photographic screening and
monitoring DR in diabetic patients (Aiello 2003).
People with DR are referred to ophthalmologists for confirmatory
diagnosis and treatment of visually impairing complications such
as proliferative retinopathy or CSMO. Nearly three decades ago,
the ETDRS study showed that grid or focal laser photocoagulation
reduces the risk of moderate visual loss by 50% in patients with
CSMO (ETDRS 1985).
Recent studies found that intravitreal steroids (Grover 2008) or,
in particular, antiangiogenic therapy with anti-vascular endothe-
lial growth factor (anti-VEFG) properties, also injected intravitre-
ally, may improve vision in patients affected by macular oedema
due to DR (Cunningham 2005; DRCR Network 2007a; DRCR
Network 2010; RESOLVE 2010; Virgili 2014).
Index test(s)
Optical coherence tomography (OCT) produces cross-sectional
images of optical reflectivity in the retina, analogous to an ultra-
sound B-scan but with higher resolution (Hee 1998). Measure-
ments of retinal thicknessmay be obtained directly from the tomo-
grams either by manually measuring the distance between the in-
ner and outer retinal boundaries or by using computer image pro-
cessing techniques. Optical coherence tomography is increasingly
used for detecting macular oedema in people with DR because
OCT is an objective and reliable tool (DRCR Network 2007b).
Furthermore, OCT allows a quantitative follow-up of the effects
of treatment and has become a tool for routine management of
macular oedema by ophthalmologists (Schimel 2011).
Other macular changes are of interest to researchers and clinicians
using OCT, such as macular hyporeflective cavities or cysts due
to fluid accumulation, subretinal fluid, or a thickened adherent
hyaloid suggestive of vitreous traction (Chan 2005). Newer spec-
tral domain OCT devices have higher resolution than previously
andmay show further abnormalities of the retinal layers, including
those of the photoreceptor layer (Alasil 2010). However, because
the construct underlying DMO is that of thickening, we will only
consider thickness-related measures in this review.
This review is a diagnostic test accuracy review aimed at investi-
gating the performance of OCT for detecting an anatomic target
condition (DMO and particularly its severe form, CSMO). The
target condition was shown several years ago to be relevant to af-
fected people in terms of prognosis and an indication for treatment
(ETDRS 1985). However, the increasing availability of OCT de-
vices, coupled with their precision and the ability to inform on
retinal layer structure, make OCT increasingly recognised as the
new reference standard for assessment of DMO, even in screening
settings (Olson 2013; Ontario HTA 2009). Thus, this review will
not be updated further.
Clinical pathway
In the updated version of this review, we acknowledge that the
clinical pathway of patients with DMO is unclear and probably
dependent on the country and setting. Thus, the applicability of
the results of the review will depend on patient selection in in-
cluded studies, such as inclusion criteria and results of prior testing.
Different levels of care may include DR screening programmes of
diabetic patients (Hautala 2013; Peto 2012), DR detection by op-
tometrists and other non-medical eye care professionals in public
or private eye care settings, and diagnosis and treatment in sec-
ondary or tertiary care by ophthalmologists or retinal specialists.
Diabetic retinopathy screening bymeans of non-mydriatic fundus
photography and telemedicine is now established in many coun-
tries (Andonegui 2012; Mansberger 2013; Peng 2011; Peto 2012;
Vaziri 2013). The increasing availability and decreasing cost of
OCT devices is making OCT attractive as a means of improving
DMO detection within photographic telemedicine programmes,
especially for reducing false positive referrals compared to fundus
imaging alone (Adhi 2013; Mackenzie 2011; Olson 2013).
In many European and North-American countries, optometrists
or other professionals may screen referred or self-referred patients
for some ocular diseases, such as diabetic retinopathy or glaucoma,
and then refer some patients to ophthalmologists based on tests
such as fundus examination or photography and ocular pressure
measurement. Other countries, such as Italy, rely on ophthalmol-
ogists for primary care needs. There is an interest in using OCT
devices at this level of care (Shelton 2013).
Patients referred fromprimary care to ophthalmologists for suspect
DR are first assessed by means of fundus biomicroscopy. There-
fore, OCT and fluorescein angiography are used if DMO or pro-
liferative retinopathy are found. In countries such as the UK, the
choice between antiangiogenic therapy and laser also depends on
OCT thickness, following the decision of the National Institute
for Clinical Excellence (NICE 2011) of reimbursing ranibizumab
only if central retinal thickness is 400 µm or more, based on a
subgroup analysis of the RESTORE 2011 study.
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The classification of DMO to decide on treatment options is not
standardised and may ultimately depend on the ophthalmologist’s
assessment of several clinical components. These may include vi-
sual acuity and the chronicity of the condition, the existence of
a thickened and adherent hyaloid, an epiretinal membrane and
vitreous traction to the retina, the degree of ischaemia and the pre-
sumed “vasogenic” origin which was believed to benefit more with
laser photocoagulation compared to the diffuse type (Bandello
2010). Optical coherence tomography is able to display some of
these features, particularly the vitreous-retina interface, as well as
any subretinal fluid, the integrity of the photoreceptor layers, and
patterns of uncertain interpretation such as hyperreflective foci
(Framme 2012; Yohannan 2013). The attempt to classify DMO
in focal or diffuse patterns in clinical trials, based on the amount of
leakage from microaneurysms, failed to show an impact on prog-
nosis and the response to angiogenic therapy (RESTORE 2011).
In addition, such classification was found to have been used incon-
sistently (Browning 2008c). Diagnostic questions related to these
features are complex and cannot be investigated in the diagnostic
accuracy framework, according to our judgement.
Prior test(s)
In the accuracy framework in which OCT is used in primary
care to detect DMO and then verified by an ophthalmologist
with fundus biomicroscopic examination, prior testing should be
fundus examination or photography interpreted by optometrists,
trained nurses, general practitioners, or automated software.
Role of index test(s)
Given the ill-defined nature and the complexity of clinical path-
ways, plus the increasing importance of OCT, this updated review
differs from the original version. It reinforces the statement that
DMO detection primarily by means of OCT, followed by referral
to an ophthalmologist using fundus biomicroscopy as verification,
is an accuracy question that can be relevant only in specific settings
in which this pathway is followed; perhaps in some primary eye-
care settings (Shelton 2013).
When ophthalmologists have to decide on treatment and progno-
sis of DMO, OCT has a dominant role, and in this revised review
we agree that fundus examination cannot be used as a reference
standard in clinical contexts (Ontario HTA 2009). At this step of
care, research has focused on the patterns of agreement between
OCT and fundus examination (Davis 2008), and particularly on
the clinical characteristics of subclinical DMO, which is detected
by OCT as a retinal thickness in the 225 µm to 300 µm range
in the absence of biomicroscopic detection of CSMO (Bhavsar
2011; Browning 2008a; Browning 2008b; DRCRNetwork 2012;
Pires 2013). In fact, landmark ETDRS 1985 and ETDRS 1995
studies on photocoagulation showed that DMO less than CSMO
may have a good prognosis and less benefit, compared to those
with CSMO, with photocoagulation compared to observation.
Recently, OCT has offered additional clues on the relationship be-
tween central retinal thickness and treatment response. RESTORE
2011 showed that the gain in vision with ranibizumab treatment
compared to photocoagulation is about the same as photocoagu-
lation when OCT retinal thickness is less than 300 µm. In 2011,
the UKNational Institute for Clinical Excellence (NICE) decided
to reimburse ranibizumab treatment only in cases where OCT
thickness is less than 400 µm (NICE 2011). Apparently contra-
dicting this finding, based on further subgroup analyses based on
RESTORE2011 data,Mitchell 2013 has shown that quality of life
gain, measured with the National Eye Institute Visual Function-
ing Questionnaire, is greater with ranibizumab than laser when
thickness is lower than 400 µm and vision is better than about 68
letter, or about 20/50. These results are difficult to interpret since
the subgroups are small and because vision-related quality of life is
conventionally presumed to be dependent on the eye with better
vision, although visual loss in diabetic patients is not only more
symmetric but also milder than in age-related macular degenera-
tion.
Alternative test(s)
Despite the fact that retinal thickness measurements with OCT
have been compared to those obtained using the Retinal Thickness
Analyzer in at least one study, such a comparison is no longer of
interest given the dominant use of OCT devices (Goebel 2006).
Therefore, OCT is the only index test evaluated in this review.
Rationale
When this review was first published, it was important because
OCTwas increasingly used at all levels of care to confirm the pres-
ence or absence of DMO and to monitor treatment outcomes. As
stated before, at present the results of this reviewmay be applicable
to inform decisions only in specific contexts.
O B J E C T I V E S
To determine the diagnostic accuracy of OCT for detectingDMO
and CSMO, defined according to ETDRS 1985, in patients re-
ferred to ophthalmologists after DR is detected. In the update of
this review we also aimed to assess whether OCT might be con-
sidered the new reference standard for detecting DMO.
Secondary objectives
1) Heterogeneity investigation
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To determine which retinal thickness cut-off or which OCT al-
gorithm yields the best diagnostic performance. In fact, clinicians
may use different thresholds of retinal thickness to define DMO
and CSMO. Furthermore, thickness can be calculated using dif-
ferent algorithms (such as, previously, central point thickness or,
currently, central subfield thickness, whichwere found to be highly
correlated in DRCR Network 2008) or other algorithms that try
to detect paracentral retinal thickening (Sadda 2006).
Based on a previous systematic review on this topic, conducted
by some of the authors (Virgili 2007), we initially planned to
investigate the following sources of clinical heterogeneity.
A. Heterogeneity related to retinal thickness cut-off
We originally planned to explore which cut-off value of central
retinal thickness represents the best trade-off of sensitivity and
specificity for clinical use. We selected only two pre-planned cut-
offs because data driven cut-off selection has been found to lead
to optimistic estimates of sensitivity and specificity, especially in
small studies (Leeflang 2008). Based on the Virgili 2007 review,
we expected to report on a sensitive and a specific threshold, cor-
responding to values of 250 µm and 300 µm (± 25 µm for both
cut-offs). However, only one study reported both thresholds and
we used the available information as explained later in the review.
Furthermore, the calibration of different OCT devices was found
to vary, making the effect of using a specific threshold inconsistent
(Wolf-Schnurrbusch 2009).
B. Heterogeneity related to index test
1. Which OCT definition of CSMO should be preferred,
such as using the central thickness subfield or complex diagnostic
algorithms?
2. What is the difference between OCT models of different
generations which were found to yield different measurements
(Forooghian 2008; Kiernan 2009; Wolf-Schnurrbusch 2009)?
C. Heterogeneity related to reference standard
1. What is the impact of the type of reference standard used,
i.e. stereophotography, contact or non-contact lens
biomicroscopy?
D. Heterogeneity related to characteristics of the study popu-
lation
1. What is the performance of OCT in higher versus lower
prevalence studies? (Taking into account that we planned to
include clinic-based series, a level of prevalence around 30% was
considered a priori.)
E.Heterogeneity related tomethodological study quality items
See Appendix 1 of the QUADAS 2 checklist (Whiting 2011)
which replaced QUADAS (Whiting 2003) in the update of this
review. We dichotomised QUADAS 2 items using yes versus other
categories and planned to use a Risk of Bias or Applicability as
covariate if the smaller subgroup included at least three studies.
2) To assess whether OCT might be considered
the new reference standard
The updated version of this review included an introductory sec-
tion on the clinical pathways and the role of the index test, which
is now a mandatory item in RevMan 2012. The diagnostic accu-
racy framework is valid if the clinical reference standard is the best
available method for establishing the presence or absence of the
target (Bossuyt 2008) and implies that, in patients with discordant
results, the reference standard is true and the index test is wrong.
Diagnostic studies can take the “agreement” rather than the “ac-
curacy” perspective to compare OCT and fundus examination,
implying that neither test was believed to be more valid than the
other. Browning 2008b; Ockrim 2010; Olson 2013 and Ontario
HTA 2009 believed that OCT is more sensitive than clinical ex-
amination or stereoscopic fundus photography for the detection of
retinal thickening. Lord 2006 and Lord 2009 advised that when-
ever clinicians use a new diagnostic test because it is more sensitive
than an old test, they need to be clear about the assumptions link-
ing this evidence to improved patient outcomes, such as evidence
that the new test detects the same spectrum of disease as the old
test, or that similar treatment efficacy exists across the spectrum
of disease. Although this issue is not an aim of our review, and
we did not try to systematically investigate it, it is clearly key in
interpreting and using our results and will be discussed based on
articles assessed during the preparation of this review, as well as
their relevant references.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We planned to include all prospective and retrospective consecu-
tive series of patients and case-control studies that evaluated the
accuracy ofOCT for diagnosingDMO.As discussed above, we ac-
knowledge that the clinical pathway is unclear and may vary across
settings and countries. Therefore, we accepted studies in which a
two-by-two table was presented which crossed the results of OCT
retinal thickness, dichotomised at the approximate thresholds of
interest, with ophthalmologists’ detection of DMO or CSMO by
means of fundus biomicroscopy or photography as defined later.
We recorded the settings in which patients were recruited and ex-
amined in each study.
Participants
Included participants were people referred to ophthalmologists
because they had been found to have some level of DR, expectedly
by primary care professionals, such as optometrists, diabetologists
and general practitioners, or by other ophthalmologists.
6Optical coherence tomography (OCT) for detection of macular oedema in patients with diabetic retinopathy (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Prevalence is often an indicator of severity of disease spectrum
in a study. If patients with any level of DR were examined, the
prevalence of DMO would be expected to be lower than 10%
(Williams 2004; Yau 2012). However, a relatively high prevalence
of DMO was expected, as found in studies included in a previous
systematic review (Virgili 2007) and conducted in retina practices,
suggesting that a diagnosis of more severe DR, or even any DMO,
had already been carried out in the study population.
Index tests
The index test was OCT, regardless of the generation of develop-
ment of the instrument (low or high resolution, three-dimensional
or spectral-domain OCTs).
Despite the fact that retinal thickness measurements with OCT
have been compared to those obtained with the Retinal Thickness
Analyzer in at least one study (Goebel 2006), based on our knowl-
edge we believe that such a comparison is no longer of interest
given the dominant use of OCT devices. We are not aware of any
other instruments that can be compared to OCT.
Target conditions
Our review considered the target conditions as both the general
definition of DMO and its most severe type, CSMO. In fact,
finding the milder form of DMO still has implications regard-
ing the need for closer follow-up as well as on visual prognosis
(ETDRS 1985). The ETDRS definitions of DMO and CSMO
were adopted in the original version of this review because these
definitions have proven prognostic value and CSMO has repre-
sented for years the main indication for focal or grid laser photo-
coagulation (ETDRS 1985); although this treatment technique is
less used with the advent of antiangiogenic therapy (Virgili 2014).
The most common type of CSMO is the central type, defined
as retinal thickening within 500 µm of the centre of the macula
or, alternatively, hard exudates within 500 µm of the centre of
the macula and with thickening of the adjacent retina. The non-
central type of CSMO is less common and is defined as a zone of
retinal thickening, one disc area or larger, any portion of which is
located within one disc diameter from the centre of the macula.
Anatomic lesions different from retinal thickening such as the
presence of intraretinal cysts, retinal layer abnormalities (Alasil
2010; Yohannan 2013), or a thickened posterior vitreous surface
adhering to themacula, which is better seen usingOCT, have been
suggested to be relevant features of DMO in OCT (Chan 2005).
However, there is currently no widely accepted standard to define
and report these clinical and OCT aspects and to relate them
to the ETDRS definitions of DMO and CSMO, which rely on
retinal thickening. Finally, we did not take into account the role of
other biomicroscopic findings, including a thickened hyaloid, and
their influence on the diagnostic performance of OCT in DMO
patients.
Reference standards
In the ETDRS study DMO was defined on the basis of stereo-
scopic fundus photography (ETDRS 1985). This technique is
complicated and difficult to use in a clinical setting. It was re-
placed by contact fundus biomicroscopy, which was found to
be in close agreement with stereophotography, particularly for
CSMO (Kinyoun 1989). Non-contact fundus biomicroscopy is
more commonly used, since sophisticated fundus lenses have been
proposed for binocular fundus observation during the past two
decades, yet it has been shown to be slightly less sensitive than
contact fundus biomicroscopy in the study conducted by Brown-
ing et al (Browning 2004).
When this reviewwas conceived,we considered that valid reference
tests were stereoscopic fundus photography and contact lens or
non-contact lens biomicroscopy of the fundus. As reported above,
in the update of this review, we acknowledge that OCT is increas-
ingly thought of as a new reference standard for DMO (Olson
2013; Ontario HTA 2009) and will not update the review further.
Although the American Academy of Ophthalmology’s Preferred
Practice Patterns (AAO PPP 2012) still considers clinical exam-
ination as the current recommendation for routine diagnosis of
DMO, Schneider 2013 found that the use of OCT has greatly
increased for patients with neovascular age-related macular degen-
eration or DMO in recent years, while that of fluorescein angiog-
raphy or fundus photography has decreased.
Search methods for identification of studies
Electronic searches
We searched the Cochrane Database of Systematic Reviews
(CDSR), the Database of Abstracts of Reviews of Effects (DARE),
theHealth Technology Assessment Database (HTA) and theNHS
Economic Evaluation Database (NHSEED) (The Cochrane Li-
brary 2013, Issue 5), Ovid MEDLINE, Ovid MEDLINE In-Pro-
cess and Other Non-Indexed Citations, Ovid MEDLINE Daily,
Ovid OLDMEDLINE (January 1946 to June 2013), EMBASE
(January 1950 to June 2013), Web of Science Conference Pro-
ceedings Citation Index - Science (CPCI-S) (January 1990 to June
2013), BIOSIS Previews (January 1969 to June 2013), MEDION
and the Aggressive Research Intelligence Facility database (ARIF).
We did not use any date or language restrictions in the electronic
searches for trials. We last searched the electronic databases on 25
June 2013.
See: Appendices for details of search strategies for The Cochrane
Library (Appendix 2), MEDLINE (Appendix 3), EMBASE (
Appendix 4), CPCI-S (Appendix 5), BIOSIS Previews (Appendix
6), MEDION (Appendix 7) and ARIF (Appendix 8).
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Searching other resources
We handsearched the following journals from 2000 to 2009:
American Journal of Ophthalmology; Archives of Ophthalmol-
ogy; British Journal of Ophthalmology; Investigative Ophthal-
mology and Visual Science; Ophthalmology and Retina.
We also handsearched the references of the articles obtained in
full-text.
Data collection and analysis
Selection of studies
The assessment of the titles and abstracts for eligibility was con-
ducted independently by two review authors. We planned to sort
abstracts into ’definitely exclude’ and ’possibly include’ categories,
recognising that sometimes it is not possible to judge from the
abstract whether a reference fulfils the criteria or not. All abstracts
selected by at least one review author were placed in the ’pos-
sibly include’ category and we retrieved the corresponding full-
text reports and further independently assessed their eligibility as
’include’ or ’exclude’. This was done by two review authors. Dis-
agreements at each step were resolved by discussion between the
two review authors and a third senior author.
Data extraction and management
We extracted data on the number of:
• true positives (TP), i.e. patients categorised as diseased by
both the reference and index test;
• false negatives (FN), i.e. patients categorised as diseased by
the reference test, but as non-diseased by the index test;
• true negatives (TN), i.e. patients categorised as non-
diseased by both the reference and index tests;
• false positives (FP), i.e. patients categorised as non-diseased
by the reference test, but as diseased by the index test;
• patients with uninterpretable index test results;
• patients with both eyes included in the analyses;
• missing data, i.e. patients included in the study but not in
the analyses, by causes of exclusion.
Uninterpretable OCT results are found when thickness is difficult
to obtain because of low quality examinations, such as when ocular
media are opaque or the pupil has very poor dilation, or both.
For each study, we recorded how these patients were treated in the
analyses.
The data were extracted independently by two review authors to
ensure consistency and entered in to Review Manager (RevMan
2012).
Assessment of methodological quality
In the updated of this review, the review authors moved to
QUADAS 2 (Whiting 2011) tool to assess the susceptibility to bias
of the included studies, based on guidance presented in Appendix
1. Additional quality items were on study sponsorship and the unit
of analysis issue which is specific to ophthalmology, such as when
analyses included both eyes of some individuals. The method-
ologic quality of the included studies was assessed independently
by two review authors and disagreement on study quality was re-
solved by a third senior author.
Statistical analysis and data synthesis
We conducted two separate analyses, one for each definition of the
target condition; that is DMO and its more severe form CSMO.
We had planned to use the METADAS macro (Takwoingi 2008)
to fit hierarchical summary ROC curve (HSROC) models in SAS
for the primary analysis in this review, as well as to explore the
effect of covariates on accuracy and threshold. Harbord 2007 has
shown that the bivariate (Reitsma 2005) and the HSROC models
are mathematically equivalent and, as a result, METADAS derives
pooled sensitivity and specificity and the effect of covariates on
them. In the original version of this review we used the bivariate
model approach to assess the effect of covariates on sensitivity and
specificity, since a selection at specified thresholds was planned,
and then a meta-analysis of a few studies including a restricted
range of thresholds was possible. As in the original version, when
updating this review, we found convergence problems of the bi-
variate model with some covariates, and decided to fit theHSROC
model in SAS but still present the effect of covariates on sensitivity
and specificity, as allowed by METADAS.
Since DMO is often bilateral, there may be unit of analysis issues
in diagnostic studies on this diabetic complication. We originally
planned to consider studies as high quality if only one eye of each
individual was included or less than 10% of individuals had both
eyes included in the study. Studies including patients with both
eyes affected but only one randomly selected were also considered
as high quality. We planned to conduct subgroup analyses of high
versus low quality studies regarding this criterion to investigate
heterogeneity.
We had planned to refer to Dukic 2003 for conducting statistical
analyses that included several thresholds extracted from the same
study. However, this was not possible even in this update.
Investigations of heterogeneity
The investigations were primarily concerned with exploring het-
erogeneity in sensitivity and specificity as these are the quantities
we intended to estimate. Therefore, we used:
• forest plots to look for evidence of heterogeneity within
sensitivity and within specificity;
• ROC plots to look for evidence of a threshold effect and
heterogeneity due to differences in accuracy;
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• effects of covariates, corresponding to the sources of
potential heterogeneity listed in the ’Investigation of sources of
heterogeneity’ section, on sensitivity or specificity, or both, in the
model.
Sensitivity analyses
We planned to restrict analyses by excluding case-control studies
if they were found when updating this review. We also conducted
a sensitivity analysis restricted to newer OCT models (Stratus or
spectral-domain OCTs).
Assessment of reporting bias
We had planned to assess publication bias using funnel plots dis-
playing lnDOR on the x-axis and 1/ESS1/2 (where ESS is the ef-
fective sample size) on the y-axis, as recommended byDeeks 2005,
provided that 10 or more studies were included. However, only
nine studies were included in the largest meta-analysis.
R E S U L T S
Results of the search
The original electronic searches yielded a total of 3777 records.
After deduplication we screened 1672 titles and abstracts for po-
tential inclusion in the review; we rejected 1652 reports as they
were not relevant.Of the two authors who screened the results, one
author selected 20 reports for potential inclusion and one author
selected 17. After disagreements were discussed with a third review
author, we obtained the full-text copies of 20 studies. Of these,
11 were excluded for reasons presented in the ’Characteristics of
excluded studies’ table and nine met the inclusion criteria for our
review since they used an appropriate index and reference test in
patients having or not having DMO or CSMO as defined by the
ETDRS study.
An update search run in June 2013 yielded a further 1178 records
(Figure 1). After deduplication the Trials Search Co-ordinator
scanned 662 records and removed 573 records which were not
relevant to the scope of the review. We reviewed 89 records and
rejected 81 abstracts as not eligible for inclusion in the review. We
obtained full-text copies of eight reports for further examination.
We included one new study (Medina 2012) and excluded seven
other studies, see Characteristics of excluded studies table for rea-
sons for exclusion.
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Figure 1. Results from searching for studies for inclusion in the review.
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Methodological quality of included studies
Methodological quality is presented in Figure 2, and details are
given in the ’Characteristics of included studies’ table.
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Figure 2. Risk of bias and applicability concerns summary: review authors’ judgements about each domain
for each included study
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Participant selection
Participant selection was of unclear risk of bias since in four stud-
ies it was unclear whether patients were consecutive and only
three studies were prospective. Moreover, Goebel 2006 included
13 healthy patients (13 eyes) out of 82 participants (137 eyes) and
in Nunes 2010 all eyes had either central or non-central CSMO
and were drawn from Reading Centre records. The latter is po-
tentially too narrow as a disease spectrum but we believed it was
consistent with other studies, which limited the CSMO definition
to the central type in all but one study (Goebel 2006). CSMO
prevalence varied between 19% and 58% (median 50%) in eight
studies and in a ninth study (Nunes 2010) all eyes had either cen-
tral (N = 40) or non-central (N = 22) CSMO.Data were extracted
for detecting the central type (as 65% prevalence), since all but one
of the other studies considered only central CSMO as the target
disease.
The professional who referred patients was unclear in all studies,
althoughMedina 2012 reported referral by primary care. Previous
testing and the setting from which patients had been referred was
unclear in all studies. Thus, we scored applicability as unclear in
all studies.
Index test
Five out of 10 studies either did not report masking (blinding)
of index test result interpretation (N = 4) or mentioned a lack of
masking (N =1). All but two studies stated the retinal thickness cut
off was pre-specified. Applicability was judged to be good overall
regarding index test execution and characteristics.
Reference standard
Masking of reference standard results interpretation from index
test results was unclear for three studies. The type of reference
standard and its execution was appropriate in all studies.
Flow and timing
Three out of 10 studies neither reported on uninterpretable results
nor explained withdrawals. An additional study (Nunes 2010)
gave an unclear explanation of missing data, described as statistical
outliers in a primary analysis correlating visual acuity with retinal
thickness. The overall proportion of missing data for any cause,
that is the differences between eyes included in the study and those
analysed, was 0% to 9% in five studies reporting on them (thus,
below the 10% threshold which we planned to use for subgroup
analyses) and was 11% in a sixth study (Nunes 2010).
Additional quality items
Unit of analysis was an issue, which was recorded as poor qual-
ity for all studies but Medina 2012, since the proportion of pa-
tients with both eyes in the analysis was 68% to 95%. Medina
2012 included only one eye of 62 patients. Failure to take into
account the correlation between eyes of the same patient can lead
to too narrow estimates of the standard error of sensitivity and
specificity in the studies. Thus, 95% CIs of summary sensitivity
and specificity in our review should be wider. Although Campbell
2007 provided sensitivity and specificity estimates adjusting for
within subject correlation, using the design effect correction factor
we extrapolated data using the total number of eyes, rather than
participants, to be able to include this study in this review.
There were no overt declarations of potential conflicts of interest
in terms of the manufacturer of the OCT device being involved
in funding the research.
Findings
Ten studies included a total of 830 participants and 1436 eyes, of
which 1387 eyes contributed to the analyses (49 eyes were missing
or excluded). All studies used OCT to measure central retinal
thickness. In addition, Campbell 2007 also used retinal volume
as an outcome measure - stating that it was slightly superior to
thickness - but without a formal statistical comparison. For this
reason we reported only on the use of central retinal thickness as
the OCT outcome measure (Summary of findings).
Five studies adopted the diagnostic accuracy paradigm in their
analysis (Campbell 2007; Goebel 2006; Hee 1998; Medina 2012;
Sadda 2006) and five analysed data in terms of agreement, thus
assuming that neither test was preferable (Brown 2004; Browning
2004; Davis 2008; Nunes 2010; Strom 2002).
Although all patients were seen at specialised retina clinics, only
Medina 2012 mentioned referral by primary care practitioners,
but how the referral decision was made and what test was used
were unclear.
Diagnosis of CSMO
Nine studies provided data on 1303 eyes for the analysis onCSMO
(Figure 3; Figure 4; Summary of findings), which is themost severe
form of DMO requiring treatment. The meta-analytic summary
estimates corresponded to a sensitivity of 0.81 (95% CI 0.74 to
0.86) and a specificity of 0.85 (95%CI 0.75 to 0.91). The positive
likelihood ratio was 5.3 (3.2 to 8.7), the negative likelihood ratio
was 0.23 (0.18 to 0.30) and the diagnostic odds ratio (DOR) was
23 (13 to 40). Using OCT in a sample of 1000 people, of which
500 have CSMO, will lead to missing 98 patients (false negatives)
and will over-diagnose 77 patients (false positives).
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Figure 3. Forest plot of OCT for detection of CSMO.
Figure 4. Summary ROC Plot of OCT for detection of CSMO.
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Subgroup and sensitivity analyses for diagnosis of CSMO
Among relevant pre-planned covariates, no overall effect of low
risk of bias (vs unclear and high risk of bias) could be demonstrated
for any QUADAS 2 domain, with P values larger than 0.6 in all
analyses.
We present subgroup analyses for other covariates in Table 1. Only
prevalence had a statistically significant effect on the overall model
parameters, but including the study atmedian prevalence (Medina
2012; 50% patients with CSMO) in the high prevalence (P =
0.011) or low prevalence (P = 0.109) group caused the overall co-
variate effect to cross the nominal statistical significance threshold.
The exclusion of two studies (Goebel 2006; Hee 1998) using an
obsolete OCT model (OCT 2000) did not change the pooled
estimate (sensitivity: 0.83, 95% CI 0.75 to 0.88; specificity: 0.85;
95% CI 0.72 to 0.93).
Additional information on completeness of reporting
Retinal thickness cut-off
We describe in more detail how studies reported and analysed
accuracy at different retinal thickness thresholds since this is a key
issue for applicability. In fact, macular thickness cut-off with OCT
was variably reported. Brown 2004 presented a figure with cut-
offs at 200 µm, 300 µm and 400 µm. Browning 2004 used the
upper limit of the normal range for each subfield (265 µm for
the central subfield). Campbell 2007 reported on cut-offs from
190 µm to 240 µm, and we used the thickest value because it
was the closest to those pre-specified in this review. Davis 2008
used a cut-off of 246 µm and quoted an unpublished study on
260 individuals, conducted by the OCT producer, which found
that this was the upper limit for normality (mean + 2 standard
deviations (SDs); we rounded this up to 250 µm for descriptive
purposes). Goebel 2006 used a cut-off of 230 µm for the central
subfield. Hee 1998 presented a figure with the crude number of
eyes with and without CSMO at 25 µm from 100 µm to 800 µm,
andwe extracted data at a cut-off of 250 µmbecause itwas themost
commonly used in studies included in this review. Sadda 2006 used
theMG5 algorithm to detect both central and non-central CSMO
and provided data separately for both types; they used a cut-off of
300 µm for central CSMO and we used this value for the whole
sample in subgroup analyses by retinal thickness cut-off because
sensitivity and specificity were nearly identical for the two types
of CSMO. Nunes 2010 used a cut-off of 262 µm computed as
two standard deviations above mean thickness of an age-matched
control population of 29 eyes of healthy volunteers. Medina 2012
compared three different spectral domain OCT models as well as
measurements in mydriasis and myosis and reported the best cut-
off in the central and eight paracentral fields.
No definite sensitivity and specificity pattern was apparent for
the two subgroups of studies using cut-offs above or below 250
µm (Table 1), which is not surprising given the narrow range of
thickness cut-offs (230 µm to 300 µm), which are clinically similar.
In fact, retinal thickness values in people with CSMO often range
between 300 µm and 600 µm, or even more.
Missing data
Information on missing data, that is participants included in the
study but not analysed, was available for Brown 2004 (3%), Davis
2008 (6%), Goebel 2006 (9%), and Nunes 2010 (11%) at the eye
level. There were no missing data for Campbell 2007 and Strom
2002. Such informationwas not fully available for Browning 2004,
Hee 1998 and Sadda 2006. Owing to incomplete reporting of the
various types of missing data and the small amount when reported,
we did not undertake subgroup analyses for this item as planned in
the protocol. We observed that the overall proportion of missing
data was small, when reported, although this may impact sensitiv-
ity and specificity estimates since few counts are often recorded at
their numerator.
Diagnosis of DMO
Three studies provided data on 258 eyes included in this analysis
onDMO(Figure 5). Sensitivitieswere 0.78 (95%CI0.66 to 0.87),
0.84 (95% CI 0.70 to 0.93) and 1.00 (95% CI 0.77 to 1.00), and
specificities were 0.82 (95% CI 0.66 to 0.92), 0.79 (95% CI 0.54
to 0.94), and 1.00 (95% CI 0.95 to 1.00), respectively, in Goebel
2006; Sadda 2006, and Strom 2002; the latter reported perfect
sensitivity and specificity. We did not compute pooled estimates
of sensitivity and specificity of OCT to detect DMO because only
three studies provided data for this analysis; one of which yielded
a perfect performance.
Figure 5. Forest plot of OCT for detection of DMO.
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Disagreements between OCT and fundus
biomicroscopy
As reported before, the diagnostic accuracy framework is valid if
the clinical reference standard is the best available method for es-
tablishing the presence or absence of the target (Bossuyt 2008)
and implies that, in patients with discordant results, the reference
standard is true and the index test is wrong. The included study
Medina 2012 is a recent example of a study in which such a di-
agnostic accuracy question has been made again on OCT testing
for DMO. In these cases, it is important to investigate whether
additional information is offered by the newer, or index, test in
case of disagreements.
We did not find studies which used both OCT and fundus pho-
tography or biomicroscopy to detect CSMO and simultaneously
tried to resolve all disagreements using a fair ’umpire’ test, such as
concurrent testing, prognosis or treatment response, a methodol-
ogy which has been advised to accept a new diagnostic test as a
better reference standard (Glasziou 2008). DRCRNetwork 2007c
compared the correlation of OCT and photography with visual
acuity, both cross-sectionally and longitudinally, but did not use
the standard CSMO definition and did not specifically address
disagreements.Hereafter we report on some useful studies on spec-
trum of disease and prognosis in cases of disagreement between
our index and reference tests (Bhavsar 2011; Browning 2008a;
Browning 2008b; DRCR Network 2012; Pires 2013), which are
useful to examine the characteristics of OCT false positives which
disagree with fundus biomicroscopy or photography on the exis-
tence of CSMO.
Browning 2008b reported on retinal thickening in 100 healthy
people and 283 diabetic patients without clinically detected mac-
ular oedema. They found OCT central retinal thickness exceeding
the normal range in 6% of patients with DR, nearly all of whom
had thickness values below 300 µm according to presented data.
Such thickness values are within the range of cut-offs used in stud-
ies included in this review, and in the low range of OCT retinal
thickening recorded in patients with macular oedema, which may
reach values as high as 600 µm to 1000 µm. Browning 2008b
also suggested that more cases of OCT thickening are found in
people with severe non-proliferative retinopathy. This means that
disagreements are more common in patients who were not in-
cluded in ETDRS 1985, who had mild to moderate retinopathy.
On the other hand, this is a retrospective, single physician study
and retinopathy subgroups were relatively small.
More interestingly, Browning 2008a reported on the follow-up of
153 patients with subclinical DMO, i.e. eyes with OCT thick-
ening of the macula but not meeting the CSMO definition, who
had good visual acuity and baseline central thickness of 238 µm
(SD 39 µm). They did not report on visual acuity in detail but
found that about a third of these patients progressed to CSMO
within 35 months (median follow-up 14 months), then received
laser treatment. The authors commented that “subclinical DMO
does not inexorably progress, and when it progresses, tends to do
so slowly”. These patients may resemble those with questionable
CSMO or minimal non-central macular thickening in ETDRS
1985, who were both at less risk of visual loss and had less or no
benefit from photocoagulation laser compared to those with defi-
nite oedema (ETDRS 1995).
Further research has confirmed these findings. DRCR Network
2012 screened 891 eyes among 582 study participants and found
that 43 eyes (4.8%) of 39 participants had OCT central retinal
thickness between 225 µm and 299 µm. Nine of 43 eyes (21%)
required treatment for DMO by 2 years, whereas 27% and 38%
were estimated to either have been treated or have met an OCT
worsening criterion (i.e. thickness increased by 50 µmor becoming
300 µm or more) at the one or two year visit. Nonetheless, average
visual acuity was unchanged at the time of progression in these
patients.
In 348 eyes with type 2 diabetes and non-proliferative diabetic
retinopathy, Pires 2013 found that 6 out of 32 eyes/patients pre-
senting subclinical DMO at baseline developed CSMO (18.7%),
while 20 out of 316 eyes without subclinical DMO developed
CSMO (6.3%) within two years.
Bhavsar 2011 followed for an average of 19 months a total 124
eyes of 73 diabetic patients of whom 52 eyes of 37 diabetic patients
with subclinical CSMO in one or both eyes, whereas a control
group included 72 eyes of 36 patients without macular oedema.
Sixteen eyes of 13 subjects (35%) progressed to CSMO in the
study group, compared with six eyes of four subjects (11%) in the
control group. They found a 15% increase in odds of progression
with each 10 µm increase in central macular thickness. Thus,
we agree with Browning 2008a that such extra cases should be
monitored more closely.
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Summary of findings
Optical coherence tomography for detection of macular oedema in patients with diabetic retinopathy
The presentation of the following results assumes that fundus photography or biomicroscopy are valid reference standards
for diagnosing diabetic macular oedema (DM O). Readers should be aware of the fact that additional information offered
by OCT regarding retinal thickness with respect to the reference standard is useful, specifically for false positives or
subclinical DM O, a condition that was found to increase the risk of developing clinically significant macular oedema
(CSM O).
Patients or population: patients affected by diabetic retinopathy. Setting: referral eye clinics
IndexTest: optical coherence tomography.1 Reference Test: stereoscopic fundus photography or contact lens or non-
contact lens biomicroscopy of the fundus. Threshold: proven or probable CSM O based on ETDRS definition
Test result Number of results
per 1000 patients tested (95% CI)
Quality
of the evidence
(GRADE)
M edian prevalence 500 per 1000, which is typically seen in patients with diabetes of 15 to 20 years duration since
diagnosis, older patients, and patients with additional risk factors.
All studies (697 participants, 1242
eyes, 9 studies)
Sensitivity (95% CI) 0.81 (0.74 to 0.87)
True posit ives 403 per 1000 (371 to 428 per 1000) Low2,3
False negat ives 98 per 1000 (72 to 129 per 1000)
Specificity (95% CI) 0.85 (0.75 to 0.91)
True negat ives 424 per 1000 (374 to 456 per 1000)
False posit ives 77 per 1000 (44 to 126 per 1000)
Footnotes:
1 Note: Index Test was OCT 2000 in 2 studies, Stratus in 5 studies, and Cirrus OCT in 2 studies using cut-of f ret inal thickness
230 µm to 300 µm
2 Risk of bias (-1): pat ient select ion and missing data were of concern in most studies
3 Imprecision (-1): unit of analysis issues (eyes v. individuals) may bias precision
Low prevalence 100 per 1000, which is typically seen in patients with diabetes of 5 to 10 years duration since diagnosis
and no other risk factors.
Estimates at prevalence less than 50%
(19% to 40%: 4 studies)
Sensitivity (95% CI) 0.74 (0.68 to 0.86)
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True posit ives 74 per 1000 Very low2,3,4
False negat ives 26 per 1000
Specificity (95% CI) 0.92 (0.87 to 0.97)
True negat ives 828 per 1000
False posit ives 72 per 1000
CI: Conf idence interval, OCT : Opt ical coherence tomography, ETDRS: Early Treatment Diabet ic Retinopathy Study
1 Note: Index Test was OCT 2000 in 2 studies, Stratus in 5 studies, and Cirrus OCT in 2 studies using cut-of f ret inal thickness
230 µm to 300 µm.
2 Risk of bias (-1): pat ient select ion and missing data were of concern in most studies.
3 Indirectness (-1): low-prevalence subgroup est imate is far f rom values expected in primary care.
4 Imprecision (-1): unit of analysis issues (eyes v. individuals) may bias precision.
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
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D I S C U S S I O N
Summary of main results
The results of this review must be interpreted in relation to the
role of OCT and clinical fundus examination in the diagnostic
pathway, a role that has evolved over time. The first two of the
following paragraphs, and also the Summary of findings, adopt
the diagnostic accuracy perspective with clinical fundus examina-
tion as reference standard, i.e. the true result in case of disagree-
ment with the index test. The third of the following paragraphs
summarises the literature on the additional information offered
by measuring OCT central thickness with respect to clinical ex-
amination, in support of its use as a new reference standard for
diagnosing DMO.
OCT for detecting CSMO
Our systematic review of 10 studies found that central retinal
thickness measured with OCT is not sensitive enough (0.81) nor
specific enough (0.85) to detect the central type of CSMO de-
fined using fundus examination or photography according to the
conventional ETDRS definition, which has guided for decades
the use of laser photocoagulation, until antiangiogenic therapy
became available. Of 1000 people, 500 of whom have CSMO, a
substantial proportion would bemissed (N = 98), and there would
be some over-referrals (N = 77) (Summary of findings). The thick-
ness cut-off extracted from studies included in this review ranged
between 230 µm and 300 µm, and was a median of 250 µm. The
precision of summary sensitivity and specificity estimates in this
review are likely to be inflated by the fact that both eyes of most pa-
tients were included in the studies without accounting for within
patient correlation.
In the original version of this review, prevalence was found to have
an effect on threshold so that OCT tended to be more specific and
less sensitive in studies with lower CSMO prevalence (< 50%).
Among mechanisms that may be responsible for sensitivity and
specificity varying with prevalence (Leeflang 2009), patient spec-
trum and reference standard misclassification may apply to this
review. However, in this update we found such analysis to be sen-
sitive to the inclusion of a new study (Medina 2012), in which
CSMO prevalence was at the median value among nine studies,
in the high or low prevalence subgroups.
OCT for detecting DMO
There were only three studies reporting on accuracy of OCT to
detect DMO. Two studies found moderate sensitivity and speci-
ficity (about 80%) and a third study found perfect sensitivity and
specificity (both equal to 1). Since estimates were heterogeneous
across studies, a meta-analysis was not performed.
Role of OCT as a new reference standard for
detecting DMO
While the original version of this review assumed that deciding
upon laser photocoagulation was an appropriate decision making
context for using OCT, since the biomicroscopic ETDRS defi-
nition of CSMO has been used for more than three decades for
this purpose (ETDRS 1985; ETDRS 1995), in this update of the
review we re-examined the use of OCT based on studies suggest-
ing that central retinal thickness measures with OCT can be con-
sidered a new, objective reference standard for diagnosing DMO
(Olson 2013; Ontario HTA 2009). Specifically, several studies
have shown that extra cases of DMO detected by OCT, but not
by fundus examination, i.e. the so called subclinical DMO, are
to be followed up closely due to the increased risk of developing
CSMO. Furthermore, RCTs demonstrating the superiority of an-
tiangiogenic therapy over laser photocoagulation (Virgili 2014)
have established the primary role of OCT testing for monitoring
treatment response, and, thus, in clinical practice. Finally, since
OCT is acknowledged by many to be the new reference standard
for diagnosing DMO, this review will no longer be updated.
Strengths and weaknesses of the review
Strengths
Merits of this review are a comprehensive literature search, the
quality assessment of studies and a meta-analytic summary esti-
mate of diagnostic accuracy based on recommendedmethodology.
Weaknesses
The main weakness of this review is related to the fact that no
clinical pathway could be pre-specified, nor was it reported in any
included study, and that the role of OCT has changed over the
last decade, gaining importance in the diagnostics of chorioretinal
disease.
The number of studies in this review is small and only two stud-
ies adopted the latest generation OCTs, which also record slightly
higher values of retinal thickness compared with the Stratus OCT
(Forooghian 2008; Kiernan 2009;Wolf-Schnurrbusch 2009), and
two studies used an obsolete OCT model (OCT 2000), although
their exclusion did not change the pooled estimate in a sensitivity
analysis. Liu 2014 investigated decision-making on monitoring
antiangiogenic therapy for DMO and found that newer spectral
domain OCTs rarely lead to different treatment decisions com-
pared to the Stratus OCT.
More importantly, we could not investigate the effect at pre-speci-
fied retinal thickness cut-offs on sensitivity and specificity because
data were not available in the included studies.
Another limitation of this review is that we could not obtain data
for individuals as the unit of analysis, as nine studies included
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both eyes of the majority of patients and treated them as if they
were independent of each other. Therefore, summary estimates
of sensitivity and specificity will have too narrow CIs because the
correlation between eyes of the same individual was not taken into
account. Apart from this item, at least one QUADAS 2 domain
was at unclear or high risk of bias in all studies.
Completeness of the evidence on the use of OCT
central retinal thickness as reference standard
We did not search systematically the literature on disagreements
between OCT and clinical fundus examination. However, we
found several studies showing that evidence is accumulating on
prognosis and treatment of subclinical DMO cases detected with
OCT, i.e. false positives in our review.
We found no studies on clinical and OCT findings of OCT false
negatives, i.e. cases in which ophthalmologist’s fundus examina-
tion but not OCT identifies DMO or CSMO. This problem is
particularly important for its use in the primary care setting, since
these could be missed referrals exposed to consequences of lack of
treatment until they are detected. Moreover, we found no obser-
vational studies on the consequences of withholding treatment in
these patients, that is those with CSMO who did not have central
thickening on OCT (nearly 8% at an average CSMO prevalence
of 50% in our review). A potential cause of false negative OCT
results may be the fact that, with the exception of Sadda 2006,
the included studies assessed only the central type of CSMO. Al-
though this was made explicit, it is unclear how in reality clinicians
applying the reference standard were able to handle overlapping
with the non-central type of CSMO, which is less common and
is also influenced by detection of hard exudates, which are not
included in the definition of OCT thickness-based positivity but
would be identified by concurrent fundus imaging.
Applicability of findings to the review question
Readers who wish to use and interpret the results of this review
should consider the setting and clinical pathway to which they
could be applied. The studies included in this review were carried
out in tertiary care settings and patients had a high prevalence of
CSMO, around 50%. Furthermore, we found that OCT sensi-
tivity decreased and its specificity increased at lower prevalence,
usually associated with milder disease profile, but this subgroup
analysis may not be reliable as it was based on few studies.
Newer spectral-domain OCT devices have higher resolution than
previous devices and may show further abnormalities of the reti-
nal layers, including those of the photoreceptor layer (Alasil 2010;
Yohannan 2013). However, because the construct underlying
DMO andCSMO is that of thickening, we only considered thick-
ness-related measures in this review.
Some recent RCTs on anti-VEGF treatment for macular oedema
due to DR have included patients in whom our index test and
reference standard were both positive, that is affected by clinically
detected CSMO and central retinal thickening on OCT (DRCR
Network 2010; RESOLVE 2010). Also, changes in OCT retinal
thickness were used to decide on the need for ranibizumab re-
treatment inDRCRNetwork 2010 andRESOLVE2010. This has
made OCT an essential tool to manage antiangiogenic treatment
of macular oedema in diabetic patients.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
There is substantial disagreement between OCT central retinal
thickness, used at cut-offs between 230 µm and 300 µm, and fun-
dus biomicroscopy carried out by an ophthalmologist to diagnose
CSMO. According to some studies, the characteristics of cases
of disagreement may be different and often correspond to milder
macular oedema in false positive cases. The identification if such
subclinical DMO cases is still useful, as found by Browning 2008b
and others, suggesting that these patients should be followedmore
carefully by means of clinical examination. The clinical profile of
OCT false negatives is unclear, given the studies we used and the
literature we searched while preparing and updating this review.
Although fundus biomicroscopy is still the current recommen-
dation for routine diagnosis of DMO (AAO PPP 2012), OCT
is increasingly used (Schneider 2013) and many find it the new
reference standard (Olson 2013; Ontario HTA 2009). Thus, no
further update of this review will be performed.
Implications for research
Diagnostic accuracy no longer seems to be a useful framework
to investigate the use of OCT for diagnosing DMO, given its
dominant role in modern practice (Olson 2013; Ontario HTA
2009). The clinical characteristics and outcome of disagreements
between OCT and clinical assessment of the macula to detect
CSMO would be usefully reported, especially documenting false
negative cases.
Our review also shows that the unit of analysis issue is a common
analytic issue in diagnostic research onmacular oedema in patients
with DR.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Brown 2004
Study characteristics
Patient sampling Cohort of consecutive diabetic patients with varying levels of retinopathy, examined during a 6-
week period; 59/95 severe non-proliferative or proliferative diabetic retinopathy. Both eyes selected
for 80% of subjects enrolled
Patient characteristics and set-
ting
172 eyes of 95 participants, 66% Caucasian; mean age 62 years, diabetes duration 19 years, visual
acuity 0.33 logMAR (slightly less than 6/12), treated with focal laser an average of 1.5 times.
Subjects were examined at the Retinal Vascular Center at theWilmer Eye Institute, Baltimore, USA.
Exclusion criteria included the presence of any retinal or choroidal disease, other than diabetes, that
could affect retinal thickness or preclude identification of edema involving the centre of the macula
Professional referring patients and prior testing were unclear
Index tests Stratus OCT (OCT3; Zeiss-Humphrey Systems, Dublin, CA, USA). OCT exams were carried out
by a trained OCT technician, masked to the physician’s assessment of foveal edema, using six 6 mm
radial scans. Each scan was interpreted by a second masked observer, who assessed the quality of the
OCT image and recorded the retinal thickness at the centre of the macula. Positive test defined as
central point thickness 300 µm or more based on 6 spokelike scans
No sponsorship by OCT producers declared.
Target condition and reference
standard(s)
CSMO diagnosed with fundus biomicroscopy by retina specialists. Clinical assessment of macular
oedema performed before OCT. CSMO prevalence 19%
Flow and timing Consecutive series of patients and there is no mention of a selection for stereophotography based
on OCT status. Only one reference standard. Out of 97 participants who accepted entrance in to
the study, only “2 patients were excluded after enrolment because one was unable to complete OCT
testing during the clinic visit as a result of time constraints and another left before OCT testing
without offering an explanation”. The OCT scans were of sufficient quality for interpretation in
170 (99%) of 172 cases
Comparative
Notes Research supported in part by the Wilmer Eye Institute (Johns Hopkins) Macular Research Fund,
Baltimore, MD
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
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Brown 2004 (Continued)
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Low Unclear
DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
No
Did all patients receive a refer-
ence standard
Yes
High
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Browning 2004
Study characteristics
Patient sampling Prospective case series. Patients with central or non-central CSMO in one or both eyes seen in a
private retina practice were examined for the presence of central thickening. “The study protocol
attempted to enrol consecutive patients during the period of the study, but consecutivity was not,
in fact, achieved”
Professional referring patients and prior testing were unclear
Patient characteristics and set-
ting
143 eyes of 80 patients seen at Charlotte Eye, Ear, Nose, and Throat Associates, Charlotte, North
Carolina. Demographic participants’ characteristics not reported. Patients with media opacities,
poor pupillary dilation, high refractive error, or otherwise technically unsatisfactory studies with
poor foveal thickness reproducibility were excluded
Professional referring patients and prior testing were unclear
Index tests Stratus OCT (OCT3; Zeiss-Humphrey Systems, Dublin, CA, USA). Thickness of 250 µm used
as cut-off for positive result. OCT conducted by certified ophthalmic photographers experienced
in performing OCT and masked to the results of the clinical examination. Central subfield value
from standard software retinal map used to measure thickness. No sponsorship by OCT producers
declared
Target condition and reference
standard(s)
CSMO (central type) diagnosed with stereoscopic slit-lamp biomicroscopy using a non-contact 78
dioptre fundus lens, by retina specialists. The clinical examination was masked from the results of
the OCT because all OCTs were performed after the clinical examination. CSMO prevalence 35%
Flow and timing Some patients were excluded due to media opacities, poor pupillary dilation, high refractive error, or
otherwise technically unsatisfactory studies with poor foveal thickness reproducibility, but number
not provided. Study report mentioned that “eligible patients did not participate because of their
unwillingness” but numbers not given
Comparative
Notes None
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
No
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
High Unclear
29Optical coherence tomography (OCT) for detection of macular oedema in patients with diabetic retinopathy (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Browning 2004 (Continued)
DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Unclear
Did all patients receive a refer-
ence standard
Yes
Unclear
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Campbell 2007
Study characteristics
Patient sampling Patients with diabetic retinopathy (“the degree of diabetic retinopathy in the sample was represen-
tative of the spectrum of this disease”) referred to the retina and comprehensive ophthalmology
services were prospectively enrolled
Professional referring patients and prior testing were unclear
Patient characteristics and set-
ting
34 participants (65 eyes) with type 1 or type 2 diabetes mellitus visited at university-based clinic in
Ontario, Canada.Demographic characteristics not reported. Patients were excluded if they exhibited
clinical evidence of any retinal disease other than diabetic retinopathy
Index tests Stratus OCT (OCT3; Zeiss-Humphrey Systems, Dublin, CA, USA). Central subfield thickness
(retinalmap) 240 µm or more used as positive test result. The study also used a novel retinal volume
sector analysis to detect central and non-central CSMO. This analysis examined the 5 central sectors
in the most magnified OCT output mode and was defined as the number of sectors with a volume
greater than the 95th percentile among diabetic eyes without CSMO. Hence, individual scores for
this variable ranged from 0 to 5. All participants underwent OCT and stereo fundus photography
on the same day, but no other detail given about masking
No sponsorship by OCT producers disclosed.
Target condition and reference
standard(s)
CSMO diagnosed with fundus biomicroscopy and stereophoto assessment by experienced retina
specialists, in a masked fashion
Eyes were then classified as either CSMO present or CSMO absent according to ETDRS definitions
CSMO prevalence 45%.
Flow and timing All OCT results were classified as positive or negative and no uninterpretable results or withdrawals
were reported.
Comparative
Notes Supported in part by a grant from the University of Ottawa Medical Research Fund
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Low Unclear
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Campbell 2007 (Continued)
DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
If a threshold was used, was it
pre-specified?
Yes
Unclear Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
Did all patients receive a refer-
ence standard
Yes
Low
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Davis 2008
Study characteristics
Patient sampling Prospective, consecutive case series study. Study comprised subjects with diabetic retinopathy se-
lected among those enrolled in a randomised trial on treatment of DMO at retina clinics. Partici-
pants had to be gradable for both OCT and fundus photography. Therefore, there was a selection
of patients in the study but this depended both on the index test and the reference standard
Both eyes were enrolled for some patients.
Patient characteristics and set-
ting
257 patients (462 eyes) with diabetic retinopathy and CSMO in at least one eye enrolled in a
multicentre clinical trial (USA). Some eyes had no evidence of DMO at all. Mean age 59 years; 40%
women, 65% white, 18% African American, 9% Hispanic, and 8% other races. Type 2 diabetes in
93% of the participants, mean duration of diabetes 14 years.Mean visual acuity 20/32. Retinopathy
severity was non-proliferative in 90% of eyes (32% mild to moderate, 46% moderately severe, and
11% severe)
Professional referring the patients and clinical pathway were unclear
Index tests Stratus OCT (OCT 3 or OCT 2; Zeiss-Humphrey Systems, Dublin, CA, USA). Fast macular map
central subfield thickness 250 µm or more used to define positive result. Fundus photography and
OCT were evaluated independently of each other and independently of visits preceding or after the
visit being graded. Retinal thickness in µm at the centre point, mean thickness in each of the 9
subfields, and retinal volume within the grid as a whole, were considered
No sponsorship by OCT producers disclosed.
Target condition and reference
standard(s)
CSMO diagnosed by stereophotography at photograph reading centre. CSMO prevalence 57%.
“Grading methods for DME were the same as those used in the ETDRS, except that areas of retinal
thickening and hard exudates were estimated as continuous variables rather than on ordinal scales”
Fundus photography and OCT were evaluated independently of each other and independently of
visits preceding or after the visit being graded
Flow and timing “Of the 462 eyes that were candidates for analysis, 27 (6%) were excluded because of missing or
ungradable images (OCT 10 eyes, FP 15 eyes, both 2 eyes) leaving a total of 435 eyes (309 study eyes
and 126 non-study eyes) of 257 participants. These 435 eyes were eligible for all baseline analyses
comparing OCT measurements and FP gradings.”
There were no withdrawals since these were people voluntarily participating in a randomised con-
trolled trial
Comparative
Notes Supported by a cooperative agreement from theNational Eye Institute, Grants EY14231, EY14269,
and EY14229
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
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Davis 2008 (Continued)
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Unclear Unclear
DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
No
Did all patients receive a refer-
ence standard
Yes
High
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Goebel 2006
Study characteristics
Patient sampling Patients with diabetic retinopathy of any level seen at a university-based clinic in Germany. Not
mentioned if study was prospective or retrospective and study setting. Thirteen eyes of 13 subjects
without diabetes mellitus or other vascular diseases and normal central retina shown by stereo
biomicroscopy served as controls. These were also enrolled in order to calculate the mean retinal
thickness cut-off value. Only one eye per subject was selected
Patient characteristics and set-
ting
124 eyes of 69 consecutive patients with diabetic retinopathy of any stage and 13 eyes of 13 healthy
patients; diabetic patients mean ± SD (range) age 61.1 ± 14.0 (18 to 83) years; controls 62.0 ± 16.
2 (35 to 81) years
Professional referring patients and prior testing were unclear
Index tests OCT 2000 Scanner (Zeiss-Humphrey, San Leandro, CA, USA), Software Revision A6.1. Standard
macular map central subfield thickness 230 µm or more used to define positive result. Index and
reference tests obtained independently. No sponsorship by OCT producers disclosed
Target condition and reference
standard(s)
CSMO or DMO diagnosed with digital stereoscopic fundus photography. CSMO prevalence 58%,
DMO 79%. “Assessment of SFP was done without knowing the results of OCT and RTA measure-
ments”
Flow and timing 13 eyes with ungradable fundus photograph and 6 with ungradable OCT (3 eyes excluded because
scans could not be obtained and 3 eyes were excluded due to < 50% valid measurement data)
No withdrawals reported.
Comparative
Notes None
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Low High
DOMAIN 2: Index Test All tests
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Goebel 2006 (Continued)
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
No
Did all patients receive a refer-
ence standard
Yes
High
Hee 1998
Study characteristics
Patient sampling Patients with diabetic retinopathy seen at the New England Eye Center of Tufts University. Unclear
if patients were consecutively collected
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Hee 1998 (Continued)
Patient characteristics and set-
ting
182 eyes from 107 participants with diabetic retinopathy (mean age 60 years; range 25 to 81 years)
, including 98 eyes from 55 men and 84 eyes from 52 women. On slit-lamp examination, 148
eyes were diagnosed with non-proliferative, or background, diabetic retinopathy and 34 eyes had
proliferative diabetic retinopathy
Professional referring patients and prior testing were unclear
Index tests Early, non-commercial OCT model and software (presumably prototype OCT 2000, Zeiss-
Humphrey, San Leandro, CA, USA). Macular map central subfield thickness 250 µm or more used
to define positive result (more than one cut-off could be extracted from Figure 2).
No sponsorship by OCT producers disclosed.
Target condition and reference
standard(s)
CSMO or DMO diagnosed with fundus biomicroscopy by retina specialists. CSMO prevalence
40%
Flow and timing The number of patients included in the study matches patients included in the analysis. No unin-
terpretable results or withdrawals were reported
Comparative
Notes Supported in part by N1H Grant 9-RO-I-EY11289-10, Bethesda, Maryland; MFEL
Grant N00014-94-1-0717, Arlington, Virginia; an unrestricted departmental grant from
Research to Prevent Blindness, Inc., New York, New York; and the Massachusetts Lions
Eye Research Fund, Inc, Boston, Massachusetts
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Unclear Unclear
DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
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Hee 1998 (Continued)
If a threshold was used, was it
pre-specified?
Yes
Unclear High
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Unclear Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
Did all patients receive a refer-
ence standard
Yes
Low
Medina 2012
Study characteristics
Patient sampling Quote: “A total of 62 consecutive patients with diabetes without recent loss of vision (in the 6
months before enrollment) referred by their primary care physicians to the ophthalmology services
of the participating hospitals in compliance with the standard protocol for the care of patients with
diabetes were recruited over a 9-month period. Patients were considered to be diabetic if they were
taking any glucose-lowering medication.”
“Early nonproliferative diabetic retinopathy was found in 23 patients, moderate nonproliferative
diabetic retinopathy was found in 13 patients, severe nonproliferative diabetic retinopathy was
found in 15 patients, and proliferative diabetic retinopathy was found in 11 patients. CSME was
diagnosed in 31 (50%) eyes by noncontact lens biomicroscopy. The mean corrected visual acuity
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Medina 2012 (Continued)
(Snellen) was 0.69 logMAR.”
Patient characteristics and set-
ting
Quote: “Consecutive patients with diabetes without recent loss of vision (in the 6 months before
enrolment) referred by their primary care physicians to the ophthalmology services of the partic-
ipating hospitals. Patients were considered to be diabetic if they were taking any glucose-lowering
medication. Exclusion criteria were patients with significant corneal opacities that could result in
a poor OCT signal, patients with any ocular disease other than diabetes, and patients who had
undergone any intraocular surgery, including cataract surgery. One eye per patient was studied and
the study was limited to phakic eyes.”
Comment: although referring professional is reported, prior testing is unclear
Index tests Quote: “Three commercially available SD OCT devices were used: a Topcon 3D-1000 (Topcon,
Tokyo, Japan), a Cirrus HD (Carl Zeiss Meditec, Inc, Dublin, California, USA), and a Spectralis
OCT (Heidelberg Engineering, Dossenheim, Germany).”
“Different systems cannot be used interchangeably for themeasurement of macular thickness. Thus,
although we considered edema detected by means of OCT to be present when foveal thickness was
greater than a given cutoff point, we were unable to establish a common cutoff point of retinal
thickness to diagnose macular edema when we used 3 different SD OCT instruments. OCT was
performed by clinicians unaware of the patients diagnosis.”
Comment: choice of threshold does not seem pre-specified since, in the results, the authors state
they used the best cut-off, thus potentially inflating accuracy
Target condition and reference
standard(s)
Quote: “Noncontact lens biomicroscopy of the fundus was considered the gold standard. Clinically
significant macular edema was dened according to the Early Treatment Diabetic Retinopathy Study
criteria. The diagnosis of clinically signicant macular edema (CSME) was made by an independent
ophthalmologist who was blinded to the results of the OCT measurements.”
Flow and timing Interval between OCT and reference standard not specified but we assumed this would be short for
all studies if unclear. Quote: “One eye of each patient was selected at random.”
Comparative
Notes None
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
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Medina 2012 (Continued)
Low Unclear
DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
No
High Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
Did all patients receive a refer-
ence standard
Yes
Low
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Nunes 2010
Study characteristics
Patient sampling A series of patients with type 2 diabetes classified on stereocolour fundus photography at an indepen-
dent reading centre, as having clinically significant macular oedema using the ETDRS classification,
but no other detail given
Patient characteristics and set-
ting
37 participants (70 eyes) affected by CSMO. 62 eyes of 32 participants included in the analysis.
Age mean ± SD (range) years: 64.1 ± 8.7 (44 to 79); sex (male/female): 22/14; duration of diabetes
mean ± SD (range) years: 10.8 ± 6.8 (1 to 30). Eyes with photocoagulation treatment within the
3 months before inclusion in the study and eyes with cataract or any other eye disease that may
interfere with fundus examination were excluded from the study
Professional referring patients and prior testing were unclear
Index tests Cirrus HD-OCT (Carl Zeiss Meditec, Dublin, California, USA). Cirrus HD-OCT fundus refer-
ences were coregistered to the respective colour fundus photographs and the average RT for the
500 µm diameter circle, centred at the identified foveal location, was computed resorting to thin
plate spline interpolation. Central subfield thickness 262 µm or more used to define positive result,
computed as 2 SDs above mean thickness of an age-matched control population of 29 eyes from
healthy volunteers. No sponsorship by OCT producers disclosed
Target condition and reference
standard(s)
Central (type 1) CSMO diagnosed with stereocolour fundus photography
Flow and timing 8 eyes excluded. 4 eyes excluded for segmentation errors on OCT but 4 were excluded due to being
considered outliers on the statistical analysis
Comparative
Notes None
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
No
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
High High
DOMAIN 2: Index Test All tests
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Nunes 2010 (Continued)
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
If a threshold was used, was it
pre-specified?
Yes
Unclear Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Unclear Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
No
Did all patients receive a refer-
ence standard
Yes
High
Sadda 2006
Study characteristics
Patient sampling Retrospectively review of patients referred to the Doheny Ocular Imaging Unit with a diagnosis of
DMO who underwent OCT imaging using both the MG5 algorithm
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Sadda 2006 (Continued)
Patient characteristics and set-
ting
71 eyes of 40 participants with a diagnosis of diabetic macular oedema. No other clinical charac-
teristics of sample population were reported
Professional referring patients and prior testing were unclear
Index tests Stratus OCT machine (Carl Zeiss Meditec, Inc., Dublin, CA, USA) using both the standard Fast
Macular Thickness Map (FMTM) pattern and a concentric grid pattern, Macular Grid 5 (MG5)
The MG5 algorithm was used to detect central CSMO as well as the non-central type of CSMO.
For central CSMO a cut-off retinal thickness of 300 µm was used to define positive test result. No
sponsorship by OCT producers disclosed
Target condition and reference
standard(s)
CSMOor DMOdiagnosed with fundus photography by retina specialists. CSMO prevalence 56%,
DMO 83%
Flow and timing The clinical and imaging records of 71 eyes were retrospectively reviewed. 63 cases had both scanning
protocol with correct boundary detection, and were used for the analysis
In cases in which the clinical record did not clearly categorise the CSMO, stereoscopic colour
photographs obtained for the patient were reviewed by a trained member of the Doheny Image
Reading Center in an attempt to classify the oedema. This fact was not believed to represent
differential verification, provided that trained observers were used
Comparative
Notes Supported in part byNational Institutes ofHealth, Bethesda,Maryland (grant nos.: R01 EY013516,
R01-EY013178-5, P30-EY008098); Eye and Ear Foundation, Pittsburgh, Pennsylvania; National
Eye Institute andNational Center onMinority Health andHealthDisparities (grant nos.: EY11753,
EY 03040); and an unrestricted grant from Research to Prevent Blindness, Inc., New York, New
York
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Unclear Unclear
DOMAIN 2: Index Test All tests
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Sadda 2006 (Continued)
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
If a threshold was used, was it
pre-specified?
Yes
Unclear Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Unclear Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
No
Did all patients receive a refer-
ence standard
Yes
High
Strom 2002
Study characteristics
Patient sampling A series of patients diagnosed as having diabetic macular oedema less severe than CSME or as having
untreatable CSME in one or both eyes by slit lamp biomicroscopy (before data collection) in 2
clinics in Denmark. Unclear if prospective or retrospective and if patients were referred to the clinic
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Strom 2002 (Continued)
Patient characteristics and set-
ting
96 eyes of 48 patients with diabetes were studied. Mean age 53 years; female to male ratio, 11:36;
type I to type II diabetes mellitus ratio 7:40; mean duration of diabetes: type I, 13.8 years (range
2 to 26.7), type II, 23.5 years (range 16 to 32.2). Control group of 33 eyes in 25 healthy control
participants, mean age 48.2 years, served to determine the cut-off used to define a positive OCT
result (mean + 2 SDs of normal participants)
Professional referring patients and prior testing were unclear
Index tests OCT 2000 (Zeiss-Humphrey Inc., Dublin, CA, USA, with software application version A4.1). In
each eye, six radiating cross-sectional B scans of 6 mm, were obtained by a well trained technician,
with the centre of each scan being the centre of the fovea. The OCTmaps and subjective evaluation
of stereo fundus photographs were assessed by the same person with a minimum of 7 days between
the two assessments. No sponsorship by OCT producers was disclosed. “The algorithm used for
interpolation of the OCT scans in this study compared the retinal thickness of the study eyes to a
mean value ± 2 SD of healthy control eyes.”
Target condition and reference
standard(s)
CSMO or DMO diagnosed with fundus photography by retina specialists. CSMO prevalence
17%. The subjective assessment of retinal thickening on the fundus photographs took place before
assessment of the OCT topographic maps
Flow and timing 12 eyes were excluded for the following reasons: epiretinal fibrosis (1), missing OCT scan (3), poor
photograph quality (no stereo effect) in Early Treatment Diabetic Retinopathy Study (ETDRS)
standard field 2 (4), poor photograph clarity due to lens opacification (4), and poor quality of the
OCT scans due to cataract (1). Thus, a total of 84 eyes (43 right and 41 left eyes) in 47 patients
underwent analysis
Comparative
Notes None
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Unclear Unclear
DOMAIN 2: Index Test All tests
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Strom 2002 (Continued)
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
If a threshold was used, was it
pre-specified?
Yes
Unclear Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
No
Did all patients receive a refer-
ence standard
Yes
High
CSMO: clinical significant macular oedema
DMO: diabetic macular oedema
FP: false positives
logMAR: logarithm of the Minimum Angle of Resolution
OCT: optical coherence tomography
SD: standard deviation
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Alkuraya 2006 Mean and standard deviation but no sensitivity and specificity data available
Bolz 2009 Diseased patients only.
Deak 2010 Only CSMO cases.
Gaucher 2005 Study primary objective was investigating the association of DMO and vitreous detachment. Cases were
eyes with DMO on biomicroscopy; control eyes included eyes of diabetic patients without DMO on biomi-
croscopy and OCT. Thus, both OCT and biomicroscopy were used to define disease status, which is invalid
to determine diagnostic accuracy
Giovannini 1999 No CSMO or DMO definition, mainly a follow-up study.
Goebel 2002 Mean and standard deviation but no sensitivity and specificity data available
Hannouche 2012 No sensitivity and specificity data available.
Lattanzio 2002 No sensitivity and specificity data available.
Maheshwary 2010 No sensitivity and specificity data available.
Murakami 2012a No sensitivity and specificity data available.
Murakami 2012b No sensitivity and specificity data available.
Otani 1999 CSMO definition not used for reporting data.
Otani 2010 No sensitivity and specificity data available.
Sànchez-Tocino 2002 Mean and standard deviation but no sensitivity and specificity data available
Uji 2012 No sensitivity and specificity data available.
Vujosevic 2006 No sensitivity and specificity data available.
Yang 2001 CSMO definition not used for reporting data; only 2 CSMO eyes
Özdek 2005 No sensitivity and specificity data available.
CSMO: clinically significant macular oedema
DMO: diabetic macular oedema
OCT: optical coherence tomography
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D A T A
Presented below are all the data for all of the tests entered into the review.
Tests. Data tables by test
Test
No. of
studies
No. of
participants
1 OCT for detection of CSMO 9 1303
2 OCT for detection of DMO 3 258
Test 1. OCT for detection of CSMO.
Review: Optical coherence tomography (OCT) for detection of macular oedema in patients with diabetic retinopathy
Test: 1 OCT for detection of CSMO
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Brown 2004 22 6 11 133 0.67 [ 0.48, 0.82 ] 0.96 [ 0.91, 0.98 ]
Browning 2004 42 17 8 76 0.84 [ 0.71, 0.93 ] 0.82 [ 0.72, 0.89 ]
Campbell 2007 21 1 8 35 0.72 [ 0.53, 0.87 ] 0.97 [ 0.85, 1.00 ]
Davis 2008 205 73 42 112 0.83 [ 0.78, 0.87 ] 0.61 [ 0.53, 0.68 ]
Goebel 2006 53 11 11 36 0.83 [ 0.71, 0.91 ] 0.77 [ 0.62, 0.88 ]
Hee 1998 56 10 22 105 0.72 [ 0.60, 0.81 ] 0.91 [ 0.85, 0.96 ]
Medina 2012 29 6 2 25 0.94 [ 0.79, 0.99 ] 0.81 [ 0.63, 0.93 ]
Nunes 2010 37 6 3 16 0.93 [ 0.80, 0.98 ] 0.73 [ 0.50, 0.89 ]
Sadda 2006 31 4 4 24 0.89 [ 0.73, 0.97 ] 0.86 [ 0.67, 0.96 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 2. OCT for detection of DMO.
Review: Optical coherence tomography (OCT) for detection of macular oedema in patients with diabetic retinopathy
Test: 2 OCT for detection of DMO
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Goebel 2006 56 7 16 32 0.78 [ 0.66, 0.87 ] 0.82 [ 0.66, 0.92 ]
Sadda 2006 37 4 7 15 0.84 [ 0.70, 0.93 ] 0.79 [ 0.54, 0.94 ]
Strom 2002 14 0 0 70 1.00 [ 0.77, 1.00 ] 1.00 [ 0.95, 1.00 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
A D D I T I O N A L T A B L E S
Table 1. Subgroup analyses
Covariate Subgroup N studies Sensitivity Specificity Overall P values vs no sub-
groups
Retinal thickness ≤ 250 µm 5 0.86 (0.76 to 0.92) 0.85 (0.75 to 0.92)
> 250 µm 4 0.77 (0.69 to 0.84) 0.85 (0.64 to 0.95)
P value 0.103 0.971 0.034
Prevalence
(Medina 2012
in high prevalence
group)
≥ 50% (50% to
65%)
5 0.86 (0.81 to 0.90) 0.74 (0.64 to 9.82)
< 50% (19% to
45%)
4 0.74 (0.68 to 0.80) 0.92 (0.84 to 0.97)
P value 0.004 0.002 0.011
Prevalence
(Medina
2012 in low preva-
lence group)
> 50% (56% to
65%)
4 0.86 (0.81 to 0.90) 0.72 (0.57 to 0.83)
≤ 50% (19% to
50%)
5 0.74 (0.69 to 0.84) 0.91 (0.84 to 0.95)
P value 0.148 0.018 0.109
Reference standard Biomicroscopy 4 0.78 (0.69 to 0.86) 0.89 (0.79 to 0.95)
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Table 1. Subgroup analyses (Continued)
Photography or
both
5 0.82 (0.74 to 0.88) 0.79 (0.64 to 0.89)
P value 0.474 0.193 0.653
A P P E N D I C E S
Appendix 1. Methodological quality assessment guidance for QUADAS 2
DOMAIN yes (high) no unclear
PATIENT SELECTION Describe methods of patient selection: Describe included patients (prior testing, presentation, in-
tended use of index test and setting):
Was a consecutive or random
sample of patients enrolled?
Consecutive sampling or ran-
dom sampling of patients with
DR referred to an ophthalmol-
ogist because they are suspected
of having DMO based on prior
testing, i.e. fundus examination
or photography by primary eye
care professionals
Non-random sampling or ret-
rospective recruitment of pa-
tients or selection of patients
among people already followed-
up by ophthalmologists in dia-
betic retinopathy services or eye
care hospital-based services
Unclear whether consecutive or
random sampling used
Was a case-control design
avoided?
No selective recruitment of DR
patients with or withoutDMO,
or nested case-control designs
(systematically and randomly
selected from a defined popula-
tion cohort)
Selection of either cases or con-
trol in a predetermined, non-
random fashion; or enrichment
of the cases from a selected pop-
ulation
Unclear selection mechanism
Did the study avoid inappro-
priate exclusions?
Exclusions are detailed and felt
to be appropriate, including
OCT ungradable because of
poor quality
Inappropriate exclusions are
reported, e.g. patients with
questionable DMO on biomi-
croscopy
Exclusions are not detailed
(pending contact with study au-
thors)
Risk of bias: Could the se-
lection of patients have intro-
duced bias?
Overall judgement at reviewer’s discretion, with reasons
Concerns regarding applica-
bility: Are there concerns that
Inclusion of patients with a
significant degree of diabetic
Inclusion of healthy controls
or diabetic patients with no
Unclear inclusion criteria, set-
ting and prior testing
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(Continued)
the included patients do not
match the review question?
retinopathy that may be as-
sociated with diabetic macu-
lar oedema (DMO) or are sus-
pected of having DMO; clin-
ical pathway in which clinical
verification of OCT findings is
meaningful for decision-mak-
ing, with setting and prior test-
ing reported
retinopathy, such as in case-
control studies
INDEX TEST Describe the index test and how it was conducted and interpreted:
Were the index test results in-
terpreted without knowledge
of the results of the reference
standard?
Test performed “masked” or
“independently and without
knowledge of” reference stan-
dard results is sufficient and full
details of the masking proce-
dure are not required; or clear
temporal pattern to the order of
testing that precludes the need
for formal masking
Reference standard results avail-
able to those who conducted or
interpreted the index tests
Unclear whether results are in-
terpreted independently
If a threshold was used, was it
pre-specified?
Central retinal thickness cut-
off used to dichotomise data is
declared to be pre-specified or
data at several cut-offs are pre-
sented that enable extraction in
the range of interest (250 µm to
350 µm)
A study is classified at higher
risk of bias if the authors de-
fine the optimal retinal thick-
ness cut-off post hoc based on
their own study data
No information on pre-selec-
tion of index test cut-off values
Risk of bias: Could the con-
duct or interpretation of the
index test have introduced
bias?
Overall judgement at reviewer’s discretion, with reasons
Concerns regarding applica-
bility: Are there concerns that
the index test, its conduct, or
interpretation differ from the
review question?
OCT model, OCT execution,
and OCT diagnostic criteria
clearly described and judged to
be adequate
Older OCT models, such as
OCT 2000, used or methods to
maximise the quality of results
not adopted
Insufficient details to assess this
item
REFERENCE STANDARD Describe the reference standard and how it was conducted and interpreted:
Is the reference standard
likely to correctly classify the
target condition?
Fundus stereoscopic photogra-
phy or fundus biomicroscopy
with a contact and non-contact
lens and Early Treatment Di-
abetic Retinopathy Study (ET-
DRS) definition of DMO and
Definition of DMO
and CSMO different from ET-
DRS although photography or
biomicroscopy are used
Insufficient details to assess this
item
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(Continued)
clinically significant macular
oedema (CSMO) used by an
ophthalmologist or a trained
technician in a photograph
reading centre (in case photog-
raphy is used)
Were the reference standard
results interpreted without
knowledge of the results of
the index test?
Reference standard performed
“masked” or “independently
and without knowledge of” in-
dex test results are sufficient and
full details of the masking pro-
cedure are not required; or clear
temporal pattern to the order of
testing that precludes the need
for formal masking
Index test results available to
those who conducted the refer-
ence standard
Unclear whether results are in-
terpreted independently
Risk of bias: Could the refer-
ence standard, its conduct, or
its interpretation have intro-
duced bias?
Overall judgement at reviewer’s discretion, with reasons
Concerns regarding applica-
bility: Are there concerns that
the target condition as de-
fined by the reference stan-
dard does not match the re-
view question?
Signalling question 1 high qual-
ity criteria fulfilled
Signalling question 1 high qual-
ity criteria not fulfilled
Insufficient details to assess this
item
FLOW AND TIMING Describe any patients who did not receive the index test(s) and/or reference standard or who were
excluded from the 2 x 2 table (refer to flowdiagram):Describe the time interval and any interventions
between index test(s) and reference standard
Was there an appropriate in-
terval between index test(s)
and reference standard?
’Yes’ for all studies because the
index test is commonly col-
lected with the reference stan-
dard although this is not speci-
fied
Not applicable Not applicable
Did all patients receive a ref-
erence standard?
No discrepancies between the
number of patients recruited
into the study and the num-
ber of patients in the 2 x 2 ta-
ble; or there are discrepancies
but they are motivated and are
not related to severity of dia-
betic retinopathy or presence of
DMO or CSMO
There are discrepancies or they
are motivated but related to
severity of diabetic retinopathy
or presence of DMO or CSMO
Insufficient details to assess this
item.
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(Continued)
Did all patients receive the
same reference standard?
The same reference standard
was used for all patients; dif-
ferent reference standards were
used, such as fundus photogra-
phy for some patients and fun-
dus biomicroscopy for others,
but it is clearly explained that
there was no predetermined cri-
terion that might relate the type
of reference standard to severity
of diabetic retinopathy or pres-
ence of DMO or CSMO
Different reference standards
were used, such as fundus pho-
tography for some patients and
fundus biomicroscopy for oth-
ers, and it is not clearly ex-
plainedwhether therewas a pre-
determined criterion thatmight
relate the type of reference
standard to severity of dia-
betic retinopathy or presence of
DMO or CSMO
Insufficient details to assess this
item
Were all patients included in
the analysis?
The number of patients in-
cluded in the study matches the
number in analyses or patients
with undefined or borderline
test results are excluded
The number of patients in-
cluded in the study does not
match the number in analyses
and patients with undefined or
borderline test results are ex-
cluded from the analyses
The number of patients anal-
ysed, but not that included in
the study, are reported, or un-
clear if there were inappropriate
exclusions
Risk of bias: Could the pa-
tient flow have introduced
bias?
Overall judgement at reviewer’s discretion, with reasons
Appendix 2. The Cochrane Library search strategy
#1 MeSH descriptor Tomography
#2 MeSH descriptor Tomography, Optical Coherence
#3 MeSH descriptor Ophthalmoscopy
#4 optical* near/2 coherence* near/2 tomograph*
#5 OCT
#6 (#1 OR #2 OR #3 OR #4 OR #5)
#7 MeSH descriptor Macular Edema
#8 macula* near/3 oedema
#9 macula* near/3 edema
#10 maculopath*
#11 CME or CSME or CMO or CSMO
#12 DMO or DME
#13 (#7 OR #8 OR #9 OR #10 OR #11 OR #12)
#14 MeSH descriptor Diabetes Mellitus
#15 MeSH descriptor Diabetic Retinopathy
#16 MeSH descriptor Diabetes Complications
#17 diabet*
#18 retinopath*
#19 (#14 OR #15 OR #16 OR #17 OR #18)
#20 (#6 AND #13 AND #19)
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Appendix 3. MEDLINE (OvidSP) search strategy
1. tomography/
2. tomography, optical coherence/
3. ophthalmoscopy/
4. (optical$ adj2 coherence$ adj2 tomograph$).tw.
5. OCT.tw.
6. or/1-5
7. exp macular edema/
8. (macula$ adj3 oedema).tw.
9. (macula$ adj3 edema).tw.
10. maculopath$.tw.
11. (CME or CSME or CMO or CSMO).tw.
12. (DMO or DME).tw.
13. or/7-12
14. exp diabetes mellitus/
15. diabetic retinopathy/
16. diabetes complications/
17. diabet$.tw.
18. retinopath$.tw.
19. or/14-18
20. 6 and 13 and 19
Appendix 4. EMBASE (OvidSP) search strategy
1. tomography/
2. tomography, optical coherence/
3. (optical$ adj2 coherence$ adj2 tomograph$).tw.
4. OCT.tw.
5. or/1-4
6. exp retina macula edema/
7. (macula$ adj3 oedema).tw.
8. (macula$ adj3 edema).tw.
9. maculopath$.tw.
10. (CME or CSME or CMO or CSMO).tw.
11. (DMO or DME).tw.
12. or/6-11
13. exp diabetes mellitus/
14. diabetic retinopathy/
15. diabet$.tw.
16. retinopath$.tw.
17. or/13-16
18. 5 and 12 and 17
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Appendix 5. ISI Web of Science search strategy
# 14 #4 AND #10 AND #13
# 13 #11 OR #12
# 12 TS=retinopath*
# 11 TS=diabet*
# 10 #5 OR #6 OR #7 OR #8 OR #9
# 9 TS=(DMO OR DME)
# 8 TS=(CME or CSME or CMO or CSMO)
# 7 TS=maculopath*
# 6 TS=macula* oedema
# 5 TS=macula* edema
# 4 #1 OR #2 OR #3
# 3 TS=OCT
# 2 TS=tomograph*
# 1 TS=optical* coherence* tomograph*
Appendix 6. BIOSIS Previews search strategy
# 14 #4 AND #10 AND #13
# 13 #11 OR #12
# 12 TS=retinopath*
# 11 TS=diabet*
# 10 #5 OR #6 OR #7 OR #8 OR #9
# 9 TS=(DMO OR DME)
# 8 TS=(CME or CSME or CMO or CSMO)
# 7 TS=maculopath*
# 6 TS=macula* oedema
# 5 TS=macula* edema
# 4 #1 OR #2 OR #3
# 3 TS=OCT
# 2 TS=tomograph*
# 1 TS=optical* coherence* tomograph*
Appendix 7. MEDION search strategy
Database was searched on ICPC code field. Using code “f” for ophthalmology.
Appendix 8. ARIF search strategy
optical coherence tomography AND diabet* AND *edema
WH A T ’ S N E W
Date Event Description
13 April 2015 Amended Contact details updated.
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H I S T O R Y
Date Event Description
25 June 2013 New citation required but conclusions have not changed QUADAS 2 adopted. The included study does not
change conclusions; subgroup analysis on median preva-
lence shown to be sensitive to new study allocation to
either group (low versus high prevalence)
The discussion on disagreements between OCT and the
reference standard (clinical or photographic examination)
has been updated and a secondary objective has been
added regarding whether OCT can now be considered a
new reference standard for diagnosing DMO
25 April 2013 New search has been performed Updated electronic searches yielded one new study (
Medina 2012).
C O N T R I B U T I O N S O F A U T H O R S
Conceiving the review: GV
Designing the review: GV, FM, VM, EP, FR, GC
Co-ordinating the review: GV
Data collection for the review:
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- screening search results: VM, FM
- organising retrieval of papers: VM, FM
- screening retrieved papers against inclusion criteria: VM, FM
- appraising quality of papers: VM, FM, GV
- extracting data from papers: FM, VM, EP, FR, GV
- writing to authors of papers for additional information: GV
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
We originally planned to conduct statistical analyses based on the users’ written macro gllamm in Stata Software. For the primary
analysis we used the METADAS macro to fit hierarchical sROCmodels in SAS for all analyses. In fact, we tried to fit the bivariate model
first but it did not give convergence. Then, we accepted the fact that the two models usually provide very close results and decided to
use the HSROC model. This is also justified by the fact that study specific thickness cut-offs were very close from a clinical point of
view (230 µm to 300 µm), and with only eight studies in the analysis, the effect of such similar thickness cut-offs could not be assessed
reliably.
In the 2014 update of this review, we moved fromQUADAS (Whiting 2003) to QUADAS 2 (Whiting 2011) to assess the susceptibility
to bias of included studies. We included an additional study (Medina 2012) but summary estimates of sensitivity and specificity did
not change. Because of the expanding role of OCT for diagnosing DMO, we have considered a literature review of the potential role
of OCT as a new reference standard. In particular, we have summarised the studies on the characteristics of false positives (so called
subclinical DMO) and briefly reported on the role of OCT in assessing treatment indication and response to antiangiogenic therapy.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Diabetic Retinopathy [∗complications]; Diagnostic Errors; Macular Edema [∗diagnosis; etiology; pathology]; Randomized Controlled
Trials as Topic; Retina [pathology]; Selection Bias; Sensitivity and Specificity; Tomography, Optical Coherence [∗methods]
MeSH check words
Humans
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